HealthCare Institute of New Jersey (HINJ) President and CEO Chrissy Buteas issued a statement in support of life sciences companies’ role in healthcare in response to the Trump administration’s recommendations earlier this week that women limit Tylenol use during pregnancy, unless medically necessary.
“From rigorous R&D and clinical trials to comprehensive approval and regulatory processes, life sciences companies have long partnered with safety and efficacy agencies in the U.S. and globally to ensure that patient safety remains the cornerstone of advancing human health,” Buteas said.
“They remain committed to upholding the highest standards of scientific integrity and medical safety as they pursue their mission: to improve and save lives worldwide.”
HINJ serves as the trade association for the leading research-based biopharmaceutical and medical technology companies in New Jersey, including many of the world’s largest as well as smaller, growing companies.
The Food and Drug Administration under President Trump said it is beginning the process to change the safety label on acetaminophen products and sent a letter to physicians that says the choice to take Tylenol “still belongs with parents.”
Many in the science community this week rebuked the administration’s tying of acetaminophen products to autism.
Kenvue, the New Jersey-based maker of Tylenol, said this week it “strongly disagrees” that acetaminophen causes autism and said it is “deeply concerned about the health risks and confusion this poses for expecting mothers and parents.”
“Acetaminophen is the safest pain reliever option for pregnant women as needed throughout their entire pregnancy,” the company said in a statement. “Without it, women face dangerous choices: suffer through conditions like fever that are potentially harmful to both mom and baby or use riskier alternatives. High fevers and pain are widely recognized as potential risks to a pregnancy if left untreated.”
